AbbVie Inc.

ABBV

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase3 readout (ABT-874): Apr 2009. Short interest: 1.5% of float.

Drug Manufacturers - GeneralCEO: Scott T. ReentsIPO: 2013Website ↗

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Catalysts

Phase 3Q2 2009ABT-874Moderate to Severe Plaque PsoriasisNCT00710580

Primary: Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12 (12 Weeks)Enrollment:350/350Sites: 42RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2010PlaceboAlzheimer's DiseaseNCT00948909

Primary: ADAS-Cog - Alzheimer's Disease Assessment Scale Cognition portion (Measurements up through 12 weeks.)Enrollment:274/274Sites: 29RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ4 2011ABT-450Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C VirusNCT01306617

Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12 (Week 4 through Week 12)Enrollment:50/50Sites: 11NON_RANDOMIZED, TREATMENT

Phase 2Q2 2012ABT-869Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the RectumNCT00707889

Primary: Progression-free survival (Radiographic evaluation every 2 months, clinial evaluation every 2 weeks)Enrollment:159/159Sites: 46RANDOMIZED, TREATMENT

Phase 2PositiveQ2 2014ABT-450/ritonavir, ABT-267Chronic Hepatitis C InfectionNCT01672983

Primary: Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24) (24 weeks after last dose of study drug)Enrollment:110/110RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2015Levodopa-Carbidopa Intestinal GelAdvanced Parkinson's DiseaseNCT01736176

Primary: Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score (Baseline and Week 12)Enrollment:39/39NA, TREATMENT

Phase 3PositiveQ1 2017ABT-493/ABT-530Chronic Hepatitis C, Hepatitis C Virus, HCVNCT02604017

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Mono-infected Hepatitis C Virus Genotype 1 (HCV GT1), Direct-acting Antiviral Agent (DAA) Naïve Participants in the 12-Week Treatment Arm (12 weeks after the last actual dose of study drug)Enrollment:703/703RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2017DalbavancinEndocarditis, BacteremiaNCT03148756

Primary: Number of Participants With Clinical Response at Day 84 in the Intent-to Treat (ITT) Population (Day 84)Enrollment:2/2Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3PositiveQ4 2017Placebo for AdalimumabRheumatoid ArthritisNCT02629159

Phase 2Q4 2018PlaceboMetastatic Breast CancerNCT01506609

Primary: Progression-Free Survival (PFS) (Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for PFS was 34 months.)Enrollment:294/294Sites: 120RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2020PlaceboPsoriatic Arthritis (Ps A)NCT03671148

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24)Enrollment:444/444Sites: 138RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2020PlaceboPsoriatic ArthritisNCT03675308

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24)Enrollment:964/964Sites: 256RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2021AzacitidineAcute Myeloid Leukemia (AML)NCT02993523

Primary: Overall Survival (OS) (From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021))Enrollment:443/443Sites: 172RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Sep 29, 2022VenetoclaxAcute Myeloid Leukemia (AML)NCT04102020

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1) (Up to 28 days (Cycle 1))Enrollment:112/112Sites: 156NON_RANDOMIZED, TREATMENT

Phase 3Q4 2022OnabotulinumtoxinAPlatysma ProminenceNCT04949399

Primary: Number of Participants With Adverse Events (Enrollment to Day 120)Enrollment:408/408Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2023IMGN632Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative NeoplasmNCT03386513

Primary: To assess the rate of composite CR in BPDCN patients (21-day cycle)Enrollment:179/179Sites: 28NA, TREATMENT

Phase 2Jun 13, 2024VenetoclaxRefractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic LeukemiaNCT05192889

Phase 2PositiveQ3 2024ABBV-552Alzheimer's Disease (AD)NCT05771428

Phase 3NegativeQ4 2024BOTOXEpisodic MigraineNCT05028569

Phase 2NegativeQ4 2024CVL-865SeizuresNCT04686786

Phase 3Q1 2025NavitoclaxMyelofibrosis (MF)NCT04468984

Phase 3Q2 2025AdalimumabUlcerative ColitisNCT02632175

Phase 3Q3 2025AtogepantMigraineNCT06241313

Phase 3Sep 23, 2025UpadacitinibVitiligoNCT06118411

Phase 3Q4 2025BOTOXMasseter Muscle ProminenceNCT06387394

Phase 2Q2 2026TNB-383BMultiple MyelomaNCT03933735

Primary: Number of Participants with Dose-limiting toxicities (DLT) (Day 21)Enrollment:220/220Sites: 14NON_RANDOMIZED, TREATMENT

Phase 3Q2 2026Placebo for Risankizumab SCCrohn's DiseaseNCT03105102

Phase 2Q2 2026Mirvetuximab SoravtansineRecurrent Ovarian Cancer, Folate Receptor-Alpha PositiveNCT06365853

Phase 3Q3 2026Bimatoprost SROpen-Angle Glaucoma, Ocular HypertensionNCT03891446

Phase 2Q3 2026Mirvetuximab SoravtansineAdvanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube CancersNCT06682988

Phase 3Q3 2026UpadacitinibRheumatoid ArthritisNCT05814627

Primary: Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2 (Week 12)Enrollment:487/487Sites: 218RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2026Atrophic Acne ScarsNCT05995340

Phase 2Q3 2026Telisotuzumab vedotinNon-small Cell Lung CancerNCT03539536

Phase 3Q3 2026PomalidomideMultiple MyelomaNCT03539744

Phase 2Q3 2026RanibizumabNeovascular Age-Related Macular Degeneration (n AMD)NCT04514653

Phase 3Q3 2026Mid Face Volume DeficitNCT07032597

Phase 3Q3 2026Upadacitinib 15mg DoseAtopic DermatitisNCT06389136

Phase 3Q3 2026AdalimumabJuvenile Psoriatic ArthritisNCT06100744

Phase 3Q4 2026Aflibercept (EYLEA®)AMD, n AMD, Wet Age-related Macular DegenerationNCT05407636

Phase 3Q4 2026ABBV-444Dry Eye DiseaseNCT07284381

Primary: Change from Baseline in Ocular Surface Disease Index (OSDI) Score (Baseline to Day 90)Enrollment:Target 250Sites: 20RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2026ABBV-932Generalized Anxiety Disorder (GAD)NCT06846320

Phase 2Q4 2026MEDI0618MigraineNCT06602479

Phase 3Q4 2026LutikizumabHidradenitis SuppurativaNCT06468228

Phase 3Q4 2026Ranibizumab (LUCENTIS®)AMD, n AMD, Wet Age-related Macular DegenerationNCT04704921

Primary: Mean change from baseline in Best Corrected Visual Acuity (BCVA) (At Week 54)Enrollment:671/671Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2026EluxadolineIrritable Bowel SyndromeNCT03339128

Phase 2Q4 2026ABBV-400Unresectable Metastatic Colorectal CancerNCT06107413

Phase 3Q1 2027PlaceboAtopic DermatitisNCT06701331

Phase 2Q1 2027LutikizumabRheumatoid ArthritisNCT06972446

Phase 2Q1 2027LutikizumabHidradenitis Suppurativa, Atopic DermatitisNCT06524635

Phase 2Q1 2027AzacitidineAcute Myeloid LeukemiaNCT04086264

Phase 3Q1 2027CariprazineDepression, Bipolar I DisorderNCT04777357

Phase 2Q1 2027LivmoniplimabUrothelial CarcinomaNCT06632951

Phase 3Q1 2027Risankizumab SCCrohn's DiseaseNCT06063967

Phase 3Q1 2027UpadacitinibSystemic Lupus ErythematosusNCT05843643

Phase 2Q2 2027ABBV-932Bipolar I or II DisorderNCT07220460

Phase 3Q2 2027Mirvetuximab soravtansine plus BevacizumabOvarian Cancer, Peritoneal Cancer, Fallopian Tube CancerNCT05445778

Phase 3Q2 2027UbrogepantMigraineNCT05125302

Phase 2Q2 2027LutikizumabAtopic DermatitisNCT06718101

Phase 2Q2 2027CarfilzomibMultiple MyelomaNCT02899052

Phase 3Q2 2027UpadacitinibCrohn's DiseaseNCT06332534

Primary: Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64 (At Week 64)Enrollment:Target 110Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2027UbrogepantMigraineNCT06417775

Phase 3Q3 2027VenetoclaxMyelodysplastic Syndrome (MDS)NCT04401748

Phase 3Q3 2027Upadacitinib (ABT-494)Ulcerative Colitis (UC)NCT03006068

Phase 3Q3 2027Telisotuzumab AdizutecanMetastatic Colorectal CancerNCT06614192

Phase 3Q3 2027VenetoclaxChronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple MyelomaNCT03844048

Phase 3Q3 2027RisankizumabUlcerative ColitisNCT06880744

Phase 2Q3 2027LutikizumabUlcerative ColitisNCT06257875

Phase 2Q3 2027IcalcaprantMajor Depressive DisorderNCT07276997

Phase 3Q3 2027UpadacitinibCrohn's DiseaseNCT03345823

Phase 2Q4 2027IcalcaprantBipolar I Disorder, Bipolar II DisorderNCT06696755

Phase 2Q4 2027Telisotuzumab AdizutecanNon Small Cell Lung CarcinomaNCT06772623

Primary: Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan (Up to Approximately 84 Days)Enrollment:Target 252Sites: 55RANDOMIZED, TREATMENT

Phase 2Q4 2027LutikizumabPsoriatic ArthritisNCT06865105

Phase 3Q1 2028UbrogepantMigraineNCT05127954

Phase 2Q1 2028IMGN151Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube CancerNCT07024784

Phase 2Q1 2028Telisotuzumab VedotinNon-Small Cell Lung CancerNCT06568939

Phase 2Q1 2028EmraclidineSchizophreniaNCT07145918

Primary: Number of Participants with Adverse Events (AEs) (Up to approximately 74 days)Enrollment:Target 268Sites: 7RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2028ABBV-383 (Etentamig)Immunoglobulin Light Chain (AL) AmyloidosisNCT06158854

Phase 3Q1 2028VenetoclaxChronic Lymphocytic LeukemiaNCT06428019

Phase 3Q1 2028Telisotuzumab VedotinNon Small Cell Lung CancerNCT04928846

Primary: Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) (Up to approximately 39 months)Enrollment:Target 698Sites: 316RANDOMIZED, TREATMENT

Phase 2Q1 2028Telisotuzumab AdizutecanMetastatic Colorectal CancerNCT06820463

Phase 3Q1 2028AtogepantEpisodic MigraineNCT05711394

Primary: Change from Baseline in Mean Monthly Migraine Days (Baseline (Week 0) through Week 12)Enrollment:Target 450Sites: 98RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2028RisankizumabPsoriasisNCT04862286

Phase 2Q3 2028VenetoclaxWaldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaNCT07387471

Phase 3Q3 2028UpadacitinibUlcerative ColitisNCT05782907

Phase 3Q3 2028risankizumabUlcerative Colitis (UC)NCT03398135

Phase 2Q3 2028AGN-151607-DPVentral HerniaNCT07226791

Phase 2Q3 2028Telisotuzumab AdizutecanColorectal CancerNCT06464692

Phase 3Q4 2028Primary Open Angle GlaucomaNCT06822738

Phase 2Q4 2028Neovascular Age-related Macular Degeneration, Wet Macular DegenerationNCT03999801

Phase 2Q1 2029Mirvetuximab SoravtansineOvarian CancerNCT07059845

Phase 3Q1 2029ElagolixEndometriosisNCT04333576

Phase 2Q2 2029AGN-193408 SROpen-angle Glaucoma, Ocular HypertensionNCT04499248

Phase 3Q2 2029RisankizumabCrohn's DiseaseNCT05995353

Phase 2Q2 2029VenetoclaxChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)NCT02966756

Phase 3Q2 2029Telisotuzumab adizutecanColorectal CancerNCT07525206

Phase 2Q2 2029ABBV-706Small Cell Lung CancerNCT07155174

Phase 3Q2 2029UpadacitinibJuvenile Idiopathic ArthritisNCT05609630

Phase 3Q3 2029Mid Face Volume DeficitNCT06734351

Phase 2Q3 2029ABBV-142Idiopathic Pulmonary FibrosisNCT07230288

Phase 2Q4 2029ABBV-6628Geographic Atrophy, Age-Related Macular DegenerationNCT07160179

Phase 3Q4 2029Acne ScarsNCT07207369

Phase 2Q4 2029Telisotuzumab AdizutecanColorectal CancerNCT07023289

Phase 2Jan 15, 2030Loncastuximab Tesirine and EpcoritamabAggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3BNCT07197307

Phase 2Q1 2030RisankizumabCrohn's DiseaseNCT06548542

Phase 2Q1 2030CarboplatinEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerNCT06890338

Phase 3Q2 2030UpadacitinibAlopecia AreataNCT06012240

Phase 2Q2 2030ABBV-1758Alzheimer's DiseaseNCT07599670

Phase 3Q3 2030UpadacitinibAtopic DermatitisNCT06461897

Phase 3Q3 2030ABBV-706Small Cell Lung CancerNCT07365241

Phase 3Q3 2030LivmoniplimabHepatocellular CarcinomaNCT06109272

Primary: Stage 1: Best Overall Response (BOR) per Investigator (Through Study Completion, Up to Approximately 56 Months)Enrollment:Target 660Sites: 37RANDOMIZED, TREATMENT

Phase 3Q3 2030Telisotuzumab AdizutecanNon-Small Cell Lung CancerNCT07155187

Phase 2Q4 2030Telisotuzumab AdizutecanLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal AdenocarcinomaNCT06628310

Phase 2Q4 2030ABBV-453Multiple MyelomaNCT06953960

Phase 2Q4 2030Telisotuzumab AdizutecanSolid Tumors Harboring MET AmplificationNCT07196644

Phase 3Q1 2031Breast ReconstructionNCT06575192

Phase 3Q1 2031AtogepantChronic MigraineNCT06810505

Phase 2Q2 2031DexamethasoneMultiple MyelomaNCT03314181

Phase 3Q2 2031Telisotuzumab adizutecanMetastatic Pancreatic Ductal Adenocarcinoma, PDACNCT07490301

Phase 3Q4 2031LivmoniplimabNon-Small Cell Lung CancerNCT06236438

Primary: Stage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR) (Up to 21 Months)Enrollment:Target 840Sites: 61RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2031Standard of CareNon-Squamous Non-Small Cell Lung CancerNCT07005102

Phase 3Q2 2032Pivekimab SunirineAcute Myeloid LeukemiaNCT07581002

Phase 2Q4 2032EpcoritamabNon-Hodgkin LymphomaNCT05283720

Phase 3Q1 2033Surabgene Lomparvovec (ABBV-RGX-314)Neovascular Age-related Macular DegenerationNCT07007065

Phase 3Q3 2034RisankizumabUlcerative ColitisNCT07071519

Phase 2Q1 2036EtentamigMultiple MyelomaNCT06892522

Phase 3Q1 2042EtentamigMultiple MyelomaNCT07095452

Recent News & Research

bioRxiv

Tumor-selective Mcl1 degradation by AUTAC uncouples antitumor efficacy from cardiotoxicity

# Investment Summary: AbbVie Mcl-1 AUTAC Program **Clinical/Commercial Significance:** This research demonstrates a potential solution to a major clinical liability in Mcl-1-targeted cancer therapies—cardiotoxicity—through AUTAC (Autophagy-TargeTing Chimera) technology that selectively degrades Mcl-1 in tumor cells while sparing cardiac tissue. If validated in preclinical models and clinical development, this approach could expand the therapeutic window for Mcl-1 inhibitors, particularly in hematologic malignancies where Mcl-1 dependency is common. For AbbVie, this represents intellectual property development around a selective degradation mechanism that could differentiate future oncology candidates and potentially rescue programs limited by cardiac safety concerns. **Investor Relevance:** The cardiac toxicity mitigation is material because it addresses a key regulatory and

Jun 24, 2026

bioRxiv

Dnmt3a-mutant Leukemia Stem Cells evade chemotherapy through enforced quiescence in Npm1c-Flt3ITD Acute Myeloid Leukemia

# Investment Summary: ABBV AML Pipeline Implications **Clinical Finding:** Researchers identified that DNMT3a mutations enable leukemia stem cells to evade chemotherapy by entering a quiescent state in NPM1c-FLT3ITD acute myeloid leukemia (AML), a mechanism that could explain treatment resistance in this patient subset. **Commercial Relevance:** This mechanistic insight is relevant to AbbVie's venetoclax-based AML franchise (venetoclax + hypomethylating agents dominates frontline AML), as the identified quiescence pathway may explain why certain DNMT3a-mutant patients show inferior responses and could inform patient stratification or combination strategies. The finding suggests targeting quiescence pathways alongside current standard-of-care regimens could unlock additional value in this molecularly-defined AML segment, though clinical validation would be required before commercial impact.

Jun 8, 2026

bioRxiv

Novel mouse models for perianal fistulizing Crohns disease reveal therapeutic value of interferon-gamma antagonists

# Research Summary for ABBV Investors **Clinical Finding:** Researchers developed mouse models of perianal fistulizing Crohn's disease and demonstrated that interferon-gamma (IFN-γ) antagonists provide therapeutic benefit, suggesting a previously underexploited target for this difficult-to-treat complication affecting ~30% of Crohn's patients. **Investment Relevance:** This preprint supports a potential new mechanism for treating a high-morbidity indication where current biologics (anti-TNF, anti-IL-12/23) show incomplete efficacy; however, AbbVie's current portfolio (risankizumab, upadacitinib) targets different pathways, so commercialization would require either internal pipeline assets in IFN-γ modulation or external acquisition of such programs—worth monitoring given the limited competitive landscape in fistulizing disease.

Jun 8, 2026

PubMed

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front-line hypomethylating agents and venetoclax: A retrospective Italian study.

# Investment Summary: AbbVie's Venetoclax in AML This Italian retrospective study evaluates venetoclax combined with hypomethylating agents (HMA) as frontline treatment for both newly diagnosed and secondary acute myeloid leukemia (AML), providing real-world efficacy data outside controlled trials. The findings are relevant to AbbVie's commercial venetoclax franchise, as this combination represents a standard-of-care regimen for elderly/unfit AML patients who cannot tolerate intensive chemotherapy. Real-world outcomes data demonstrating consistent efficacy and tolerability would support venetoclax's market position and reimbursement arguments, though the magnitude of any new clinical insights would determine material impact on the $4B+ annual revenue from this indication.

May 28, 2026

bioRxiv

Convection-enhanced delivery of dexamethasone in glioma suppresses myeloid inflammation while avoiding systemic toxicities

# Investment Summary: AbbVie Glioma Research **Clinical/Commercial Relevance:** This preclinical study demonstrates that local delivery of dexamethasone via convection-enhanced delivery (CED) reduces tumor-associated myeloid inflammation in glioma while minimizing systemic corticosteroid toxicities—potentially improving therapeutic efficacy and tolerability of glioma treatment. If validated in clinical trials, this approach could support development of a localized immunomodulatory therapy for high-grade gliomas (a significant unmet need with poor prognosis), though commercialization would depend on manufacturing feasibility and comparative efficacy data against existing standards of care. **Key Investor Consideration:** Early-stage preclinical findings like this have low probability of clinical translation; investors should monitor whether AbbVie advances this into IND-enabling studies and how it fits within their broader CNS oncology

May 22, 2026

AbbVie Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research